JP2003530320A5 - - Google Patents

Download PDF

Info

Publication number
JP2003530320A5
JP2003530320A5 JP2001559492A JP2001559492A JP2003530320A5 JP 2003530320 A5 JP2003530320 A5 JP 2003530320A5 JP 2001559492 A JP2001559492 A JP 2001559492A JP 2001559492 A JP2001559492 A JP 2001559492A JP 2003530320 A5 JP2003530320 A5 JP 2003530320A5
Authority
JP
Japan
Prior art keywords
thyroid
botulinum toxin
remedies
drug
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001559492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530320A (ja
Filing date
Publication date
Priority claimed from US09/504,538 external-priority patent/US6524580B1/en
Application filed filed Critical
Publication of JP2003530320A publication Critical patent/JP2003530320A/ja
Publication of JP2003530320A5 publication Critical patent/JP2003530320A5/ja
Pending legal-status Critical Current

Links

JP2001559492A 2000-02-15 2001-02-15 甲状腺疾患の治療法 Pending JP2003530320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/504,538 2000-02-15
US09/504,538 US6524580B1 (en) 2000-02-15 2000-02-15 Method for treating thyroid disorders
PCT/US2001/004990 WO2001060396A2 (en) 2000-02-15 2001-02-15 Method for treating thyroid disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012145866A Division JP2012207030A (ja) 2000-02-15 2012-06-28 甲状腺疾患の治療法

Publications (2)

Publication Number Publication Date
JP2003530320A JP2003530320A (ja) 2003-10-14
JP2003530320A5 true JP2003530320A5 (enExample) 2008-04-10

Family

ID=24006701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001559492A Pending JP2003530320A (ja) 2000-02-15 2001-02-15 甲状腺疾患の治療法
JP2012145866A Pending JP2012207030A (ja) 2000-02-15 2012-06-28 甲状腺疾患の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012145866A Pending JP2012207030A (ja) 2000-02-15 2012-06-28 甲状腺疾患の治療法

Country Status (10)

Country Link
US (6) US6524580B1 (enExample)
EP (1) EP1253933B1 (enExample)
JP (2) JP2003530320A (enExample)
AR (1) AR027442A1 (enExample)
AT (1) ATE245032T1 (enExample)
AU (1) AU2001238369A1 (enExample)
DE (1) DE60100473T2 (enExample)
ES (1) ES2199209T3 (enExample)
TW (1) TWI283177B (enExample)
WO (1) WO2001060396A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US8563257B2 (en) * 2000-03-30 2013-10-22 Diagnostic Hybrids, Inc. Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
US8293879B2 (en) 2000-03-30 2012-10-23 Diagnostic Hybrids, Inc. Methods of using chimeric receptors to identify autoimmune disease
MXPA03000014A (es) * 2000-06-28 2004-09-13 Ira Sanders Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7178059B2 (en) * 2003-05-07 2007-02-13 Egenera, Inc. Disaster recovery for processing resources using configurable deployment platform
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
EP2502930B1 (en) * 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US9511210B2 (en) 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US7708699B2 (en) * 2005-11-18 2010-05-04 Daag International, Inc. Reflexometry and hormone function
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
EP2320821B2 (en) 2008-05-09 2020-12-30 Nuvaira, Inc. Systems for treating a bronchial tree
RU2446791C2 (ru) * 2009-06-18 2012-04-10 Федеральное государственное учреждение "Северо-Западный окружной медицинский центр Минздравсоцразвития" Способ этаноловой склеротерапии кистозно-трансформированных узлов щитовидной железы
CN104856757B (zh) 2009-10-27 2017-06-23 赫莱拉公司 具有可冷却的能量发射组件的递送装置
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
EP4111995A1 (en) 2009-11-11 2023-01-04 Nuvaira, Inc. Device for treating tissue and controlling stenosis
US9011323B2 (en) * 2010-10-08 2015-04-21 Invuity, Inc. Method and apparatus for soft tissue retraction
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
EP3288626B8 (en) 2015-04-27 2025-12-10 Tulavi Therapeutics, Inc. Substances and compositions for use in blocking nerve regeneration
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
CN109790204A (zh) 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
EP4312983A4 (en) 2021-03-30 2025-01-22 Tulavi Therapeutics, Inc. METHODS AND COMPOSITIONS FOR ABLATION OF NERVES
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5789397A (en) * 1991-01-08 1998-08-04 Bone Care International, Inc. Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
DK0661989T3 (da) 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
ES2341140T3 (es) * 1993-06-10 2010-06-15 Allergan, Inc. Tratamiento de trastornos y afecciones neuromusculares con un seropositivo botulinico diferente.
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69434535T2 (de) * 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6007843A (en) 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
ATE320815T1 (de) 1997-07-15 2006-04-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6022554A (en) 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6432723B1 (en) * 1999-01-22 2002-08-13 Clinical Micro Sensors, Inc. Biosensors utilizing ligand induced conformation changes
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6432623B1 (en) * 2001-04-27 2002-08-13 Eastman Kodak Company Method for processing a photographic element comprising a simultaneously coated protective overcoat

Similar Documents

Publication Publication Date Title
JP2003520822A5 (enExample)
JP2003519666A5 (enExample)
Marks et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache
US20230105611A1 (en) Combination therapy with cgrp antagonists and clostridial derivatives
Rozen Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia
IL208184A0 (en) Glp-1, and methods for treating diabetes
CA2218857A1 (en) Clostridial toxin derivatives able to modify peripheral sensory afferent functions
Song et al. Antiemetic activity of propofol after sevoflurane and desflurane anesthesia for outpatient laparoscopic cholecystectomy
US20180243282A1 (en) Preparation and Use of Combination Enzyme and Gastrointestinal Modulator Delivery Systems
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
WO1998036728A3 (en) Sustained analgesia achieved with buprenorphine
JP2017081997A (ja) 血管の過敏反応と関連した皮膚状態を治療する方法および組成物
AR027442A1 (es) Uso de una neurotoxina para preparar una composicion farmaceutica para el tratamiento de un desorden tiroide
CN102811722A (zh) 用石房蛤毒素衍生物对触觉丧失进行的治疗
WO2002089805A3 (en) Use of regularly scheduled high dose intravenous methotrexate therapy
WO2024112527A3 (en) Methods for the treatment of thyroid eye disease
Thomas et al. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone
JP2004501104A5 (enExample)
US20210130445A1 (en) CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
US10959964B2 (en) Use of a sprayable composition comprising ambroxol
Rathbone et al. Design and development of systemic oral mucosal drug delivery systems
Di Gregorio et al. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients
Penson et al. Commentary: octreotide and hypertrophic pulmonary osteoarthropathy.
Heinen et al. Dystonic posture of lower extremities associated with myelomeningocele: successful treatment with botulinum A toxin in a six-month-old child
JP2002529515A5 (enExample)